Download PDF
Pharmacopsychiatry 2003; 36: 56-61
DOI: 10.1055/s-2003-40451
Original Paper
© Georg Thieme Verlag Stuttgart · New York

Behavioural and Psychological Symptoms of Dementia (BPSD): Effects of EGb 761®

R. Hoerr1
  • 1Clinical Research Department, Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany
Further Information

Publication History

Publication Date:
07 July 2003 (online)

Also available at
    Permissions and Reprints

Dementia patients often present with behavioural and psychological symptoms, with prevalence rates reaching 90 %. It is therefore important to know whether an antidementia drug that improves cognitive function can also reduce the burden of behavioural and psychological symptoms of dementia, and whether it can improve cognitive function in patients suffering from such non-cognitive symptoms. Therefore, three types of study with Ginkgo special extract EGb 761® (definition see editorial) were reviewed: 1) studies on patients with impairment of cerebral function or dementia associated with behavioural and psychological symptoms (BPSD); 2) studies on patients suffering from impairment of cerebral function and depression; 3) dementia studies on patient samples with a high prevalence of BPSD. Compared to placebo, EGb 761® improved these symptoms significantly in all studies that used a scale to measure the presence and intensity of BPSD. Moreover, EGb 761® was found to be superior to placebo with respect to improvement in cognitive function, daily living activities and global assessment in dementia patients suffering from BPSD. It may be concluded that EGb 761® is of particular interest to patients with dementia and BPSD since it improves both the patient’s cognitive ability and behavioural and psychological symptoms.

Key words

Ginkgo - EGb 761® - Dementia - BPSD - Depression - HAMD - SCAG

References

  • 1 Alzheimer A. Über einen eigenartigen schweren Erkrankungsprozeß der Hirnrinde.  Neurologisches Centralblatt. 1906;  23 1129-1136
    PubMedGoogle Scholar
  • 2 American Psychiatric A ssociation. Diagnostic and Statistical Manual of Mental Disorders, fourth edition. DSM-IV. Washington, DC; American Psychiatric Association 1999
    Google Scholar
  • 3 Blessed G, Tomlinson B E, Roth M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects.  Brit J Psychiat. 1968;  114 797-811
    PubMedGoogle Scholar
  • 4 Burns A, Rossor M, Hecker J, Gauthier S, Petit H, Möller H J. et al . The effects of donepezil in Alzheimer’s disease - Results from a multinational trial.  Dement Geriatr Cogn Disord. 1999;  10 237-244
    CrossrefPubMedGoogle Scholar
  • 5 Corey-Bloom J, Anand R, Veach J for the ENA 713 B352 Study G roup. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s disease.  International Journal of Geriatric Psychopharmacology. 1998;  1 55-65
    PubMedGoogle Scholar
  • 6 Drevets W C, Rubin E H. Psychotic symptoms and the longitudinal course of senile dementia of the Alzheimer type.  Biol Psychiatry. 1989;  25 39-48
    CrossrefPubMedGoogle Scholar
  • 7 Düker H, Lienert G A. KLT-Konzentrations-Leistungs-Test. Handanweisung. Göttingen; Hogrefe 1965
    Google Scholar
  • 8 Erzigkeit H. Der Syndrom-Kurztest zur Erfassung von Aufmerksamkeits- und Gedächtnisstörungen. Vaterstetten; Vless 1986
    Google Scholar
  • 9 Finkel S I, Costa e Silva J, Cohen G, Miller S, Sartorius N. Behavioral and psychological signs and symptoms of demenia: a consensus statement on current knowledge and implications for research and treatment.  Int Psychogeriatr. 1996;  8 (Suppl 3) 497-500
    PubMedGoogle Scholar
  • 10 Finkel S I. Module 1. An introduction to BPSD. In Finkel SI, editor. Behavioral and psychological symptoms of dementia. Educational Pack. Macclesfield; Gardiner-Caldwell 1998: p. 1-19
    Google Scholar
  • 11 Folstein M F, Folstein S E, McHugh P R. ”Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician.  J Psychiat Res. 1975;  12 189-198
    CrossrefPubMedGoogle Scholar
  • 12 Förstl H. Neuropathology of behavioral and psychological symptoms of dementia.  Int Psychogeriatr. 2000;  12 (Suppl 1) 77-81
    PubMedGoogle Scholar
  • 13 Guy W  (ed.). ECDEU Assessment Manual for Psychopharmacology. Rockville, Md; US Dept. of Health, Education and Welfare, National Institute of Mental Health 1976: p. 218-222
    Google Scholar
  • 14 Hamilton M. A rating scale for depression.  J Neurol Neurosurg Psychiatry. 1960;  23 56-62
    CrossrefPubMedGoogle Scholar
  • 15 Hofferberth B. The efficacy of EGb 761® in patients with senile dementia of the Alzheimer type, a double-blind, placebo-controlled study on different levels of investigation.  Human Psychopharmacology. 1994;  9 215-222
    PubMedGoogle Scholar
  • 16 Hope T, Keene J, Fairburn C G, Jacoby R, McShane R. Natural history of behavioural changes and psychiatric symptoms in Alzheimer’s disease. A longitudinal study.  Br J Psychiatry. 1999;  174 39-44
    PubMedGoogle Scholar
  • 17 Ihara Y, Hayabara T, Sasaki K, Fujisawa Y, Kawada R, Yamamoto T. et al . Free radicals and superoxide dismutase in blood of patients with Alzheimer’s disease and vascular dementia.  J Neurol Sci. 1997;  153 76-81
    CrossrefPubMedGoogle Scholar
  • 18 Kanowski S, Herrmann W M, Stephan K, Wierich W, Hoerr R. Proof of efficacy of the Ginkgo biloba special extract EGb 761® in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia.  Pharmacopsychiat. 1996;  29 47-56
    Article in Thieme ConnectPubMedGoogle Scholar
  • 19 Knapp M J, Knopman D S, Solomon P R, Pendlebury W W, Davis C S, Gracon S I. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer’s disease.  JAMA. 1994;  271 985-991
    CrossrefPubMedGoogle Scholar
  • 20 Le Bars P L, Katz M M, Berman N, Itil T M, Freedman A M, Schatzberg AF for the North American EGb Study G roup. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia.  JAMA. 1997;  278 1327-1332
    CrossrefPubMedGoogle Scholar
  • 21 Lebowitz B D. Behavioral and psychological symptoms of dementia: A clinical and research update.  Int Psychogeriatr. 2000;  12 (Suppl 1) 19-21
    CrossrefPubMedGoogle Scholar
  • 22 Levy M L, Cummings J L, Fairbanks L A, Bravi D, Calvani M, Carta A. Longitudinal assessment of symptoms of depression, agitation and psychosis in 181 patients with Alzheimer’s disease.  Am J Psychiatry. 1996;  153 1438-1443
    PubMedGoogle Scholar
  • 23 Luxenberg J. Module 2. Clinical issues. In Finkel SI, editor Behavioral and psychological symptoms of dementia. Educational pack. Macclesfield; Gardiner-Caldwell 1998: p. 1-29
    Google Scholar
  • 24 Lyketsos C G, Steinberg M, Tschanz J T, Norton M C, Steffens D C, Breitner J CS. Mental and behavioral disturbances in dementia: findings from the Cache County Study on memory in aging.  Am J Psychiatry. 2000;  157 708-714
    CrossrefPubMedGoogle Scholar
  • 25 Mancini M, Agozzino B, Bompani R. Clinical and therapeutic effects of Ginkgo biloba extract (EGb) compared to placebo in the treatment of patients affected by senile psychorganic dementia on an arteriosclerotic basis.  Gazz Med Ital - Arch Sci Med. 1993;  152 69-80
    PubMedGoogle Scholar
  • 26 Mega M S, Cummings J L, Fiorello T, Gornbein J. The spectrum of behavioral changes in Alzheimer’s disease.  Neurology. 1996;  46 130-135
    CrossrefPubMedGoogle Scholar
  • 27 Montgomery S A, Asberg M. A new depression scale designed to be sensitive to change.  Brit J Psychiat. 1979;  134 382-389
    CrossrefPubMedGoogle Scholar
  • 28 Münch G, Schinzel R, Loske C, Wong A, Durany N, Li J J. et al . Alzheimer’s disease - synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts.  J Neural Transm. 1998;  105 439-446
    CrossrefPubMedGoogle Scholar
  • 29 Oswald W D, Fleischmann U M. Nuremberg Gerontopsychological Inventory (NAI). Göttingen; Hogrefe 1995
    Google Scholar
  • 30 Porsolt R D, Martin P, Fromage S, Lenègre A, Drieu K. Anti-stress effects of EGb 761® in rodent models. In Cristen Y, Costentin J, Lacour M, editors Effects of Ginkgo biloba extract (EGb 761) on the central nervous system. Paris; Elsevier 1992: p. 135-145
    Google Scholar
  • 31 Prilipko L. The possible role of lipid peroxidation in the pathophysiology of mental disorders. In Packer L, Prilipko L, Christen Y, editors Free radicals in the brain. Berlin; Springer 1992: p. 146-152
    Google Scholar
  • 32 Ramassamy C, Christen Y, Clostre F, Costentin J. The Ginkgo biloba extract, EGb 761®, increases synaptosomal uptake of 5-hydroxytryptamine: in-vitro and ex-vivo studies.  J Pharm Pharmacol. 1992;  44 943-945
    PubMedGoogle Scholar
  • 33 Rapin J R, Lamproglou I, Drieu K, DeFeudis F V. Demonstration of the ”anti-stress” activity of an extract of Ginkgo biloba (EGb 761®) using a discrimination learning task.  Gen Pharmac. 1994;  25 1009-1016
    PubMedGoogle Scholar
  • 34 Reisberg B, Borenstein J, Salob S P, Ferris S H. Behavioral symptoms in Alzheimer’s disease: Phenomenology and treatment.  J Clin Psychiatry. 1987;  48 (Suppl) 9-15
    PubMedGoogle Scholar
  • 35 Reisberg B, Ferris S H, de Leon M J, Crook T. The Global Deterioration Scale for assessment of primary degenerative dementia.  Am J Psychiatry. 1982;  139 1136-1139
    CrossrefPubMedGoogle Scholar
  • 36 Rogers S I, Farlow M R, Doody R S, Mohs R, Friedhoff LT and the Donepezil Study G roup. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease.  Neurology. 1998;  50 136-145
    CrossrefPubMedGoogle Scholar
  • 37 Rosen W G, Mohs R C, Davis K L. A new rating scale for Alzheimer’s disease.  Am J Psychiatry. 1984;  141 1356-1364
    CrossrefPubMedGoogle Scholar
  • 38 Rösler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, Stähelin H B,. et al . Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomised controlled trial.  Brit Med J. 1999;  318 633-640
    PubMedGoogle Scholar
  • 39 Sattel H, Geiger-Kabisch C, Schreiter-Gasser U, Besthorn C, Förstl H. Häufigkeit und Bedeutung ”nicht-kognitiver” Symptome bei der Demenz vom Alzheimer-Typ: produktiv psychotische Symptomatik, depressive Störungen und Störungen des Verhaltens.  Z Gerontol. 1993;  26 275-279
    PubMedGoogle Scholar
  • 40 Schubert H, Halama P. Depressive episode primarily unresponsive to therapy in elderly patients: efficacy of Ginkgo biloba extract EGb 761® in combination with antidepressants.  Geriatrie Forschung. 1993;  3 45-53
    PubMedGoogle Scholar
  • 41 Schwartz G E. Development and validation of the Geriatric Evaluation by Relative’s Rating Instrument (GERRI).  Psychol Rep. 1983;  53 479-488
    PubMedGoogle Scholar
  • 42 Shader R I, Harmatz J S, Salzman C. A new scale for clinical assessment on geriatric populations: SANDOZ Clinical Assessment Geriatric (SCAG).  J Am Geriat Soc. 1974;  22 107-113
    PubMedGoogle Scholar
  • 43 Stocksmeier U, Eberlein M. Depressive Verstimmung bei Hirnleistungsstörungen. Wirkung eines Ginkgo-biloba-Extraktes in Doppelblind-Studie überprüft.  TW Neurologie Psychiatrie. 1992;  6 74-76
    PubMedGoogle Scholar
  • 44 Weidenhammer W, Fischer B. c. I.-Skala, ein Selbstbeurteilungsverfahren zur Objektivierung leichter cerebraler Insuffizienzen. Ebersberg; Vless-Test 1987
    Google Scholar
  • 45 Weitbrecht W U, Jansen W. Ginkgo biloba extract in the treatment of primary degenerative dementia. Placebo-controlled, double-blind and comparative study.  Fortschr Med. 1986;  104 199-202
    PubMedGoogle Scholar
  • 46 Winter J C, Timineri D. The discriminative stimulus properties of EGb 761®, an extract of Ginkgo biloba.  Pharmacol Biochem Behav. 1999;  62 543-547
    CrossrefPubMedGoogle Scholar
  • 47 Zhang X Y, Zhou D F, Su J M, Zhang P Y. The effect of extract of Ginkgo biloba added to haloperidol on superoxide dismutase in inpatients with chronic schizophrenia.  J Clin Psychopharmacol. 2001;  21 85-88
    CrossrefPubMedGoogle Scholar
  • 48 Zhang X Y, Zhou D F, Zhang P Y, Wu G Y, Su J M, Cao L Y. A double-blind, placebo-controlled trial of extract of Ginkgo biloba added to haloperidol in treatment-resistant patients with schizophrenia.  J Clin Psychiatry. 2001;  62 878-883
    PubMedGoogle Scholar

Dr. med. Robert Hoerr

Leiter Geriatrie/ZNS

Dr. Willmar Schwabe GmbH & Co. KG

Willmar-Schwabe-Str. 4

76227 Karlsruhe

Germany

      >